^(99m)Tc-MIBI显像预评晚期非小细胞肺癌化疗疗效的研究  

The Value of ^(99m)Tc-methoxyisobutylisonitrile Imaging in Predicting Chemotherapy Efficacy for the Lung Cancer

作　　者：贾晓娟[1] 韩军[1] 赵华 袁彬 赵征 施常备 

机构地区：[1]中山大学附属第五医院核医学科,广东珠海519000 [2]陕西省肿瘤医院,陕西西安710061

出　　处：《中国医药指南》2013年第11期17-18,共2页Guide of China Medicine

摘　　要：目的探讨晚期非小细胞肺癌患者99mTc-MIBI摄取情况和化疗疗效的相关性。方法对32例晚期非小细胞肺癌患者治疗前行99mTc-MIBI检查,计算早、晚摄取率(ER、DR)和滞留指数(RI);患者经规范化疗和对症处理后,用CT评价治疗效果,总结ER、DR、RI和患者治疗有效性的关系。结果观察化疗有效和无效患者的99mTc-MIBI摄取:ER值分别为(2.27±0.34)和(1.81±0.23)(P<0.05);DR值分别为(2.19±0.28)和(1.73±0.29)(P<0.05);RI值分别为(-3.27±1.79)和(-2.98±3.26)(P>0.05)。结论晚期非小细胞肺癌化疗效果和99mTc-MIBI摄取浓度相关,和99mTc-MIBI的滞留情况无相关性。Objective The aim of this study is to evaluate the relation between 99mTc-MIBI images and clinical efficacy of chemotherapy in advanced NSCLC. Methods There were 32 patients of lung cancer which were done by 99mTc-MIBI SPECT/CT fusion imaging. The 99mTc-MIBI intake rate of early（ER） and delayed（DR） and 9mTc-MIBI retention index（RI） were calculated. The clinical efficacy of chemotherapy was evaluated by CT imaging. The relationship of ER, DR and RI between clinical efficacy were studied. Results The 99^99mTc-MIBI intake in effective treatment group and ineffective treatment group of ER were （2.27±0.34） and （1.81±0.23） ,DR were （2.19±0.28） and （1.73±0.29） ,Rlwere （-3.27±1.79） and （-2.98±3.26） .Conclusion There was correlation between 99mTc-MIBI intake （ER and DR） and clinical chemotherapy efficacy. And there was no correlation between 99mTc-MIBI retention index （RI） and clinical chemotherapy efficacy.

关 键 词：99MTC-MIBI 非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤]